Participated · Convertible Note · Jul 2026

Rege Nephro is developing therapies for kidney disease and is advancing a clinical pipeline in the renal space. The company is preparing for clinical trials and is using interim financing to accelerate R&D and pipeline advancement. Its recent bridge financing is intended to extend cash runway and de-risk near-term development milestones ahead of a larger Series C. Rege Nephro says this capital raise is part of a longer-term strategy to strengthen its position in renal therapies. The company plans to pursue a Series C in autumn 2026 and beyond as it progresses clinical and development activities.

Participated · Series A · Feb 2024

Anbogen Therapeutics is a clinical-stage biotechnology company based in Taipei, Taiwan, focused on developing precision anti-cancer therapies. The company was founded by Dr. Joe Shih and is committed to R&D innovations to improve cancer patient outcomes. Two of its investigational drugs, ABT-101 for NSCLC with HER2 exon20 insertion mutations and ABT-301 (to be combined with immune checkpoint inhibitors) are currently in human clinical trials. Anbogen raised funding in a Series A+ to advance its pipeline. The company intends to use the proceeds to support a Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for microsatellite stable (MSS) metastatic colorectal cancer. The company highlights MSS metastatic colorectal cancer as comprising about 95% of the metastatic colorectal cancer population that does not benefit from immune checkpoint inhibitors. Anbogen Therapeutics is a clinical-stage biotech headquartered in Taipei, Taiwan, focused on developing precision anti-cancer small molecules. The company’s two lead candidates are ABT-101, a HER2-targeting tyrosine kinase inhibitor, and ABT-301, a small molecule that potentiates immune checkpoint inhibitors. ABT-101 has shown substantial potency and safety in preclinical studies and a phase 1b trial, with superior selectivity against HER2 exon 20 insertion mutations. ABT-301 completed a phase 1 trial and demonstrated superior safety and pharmacokinetic profiles versus similar marketed drugs; repeated animal studies show strong synergy with anti-PD‑1/PD‑L1 therapies, including activity in MSS colorectal cancer models and modulation of the tumor microenvironment to increase killer T cell infiltration. The company says clinical signs of safety and benefit have been observed in non-small cell lung cancer patients, including sustained tumor suppression in patients previously resistant to Enhertu. Led by CEO Dr. Tsu-An Hsu and General Manager Joe Hsueh, Anbogen positions its programs to address national medical needs and accelerate development toward improved cancer treatments.

Participated · Series B · Jan 2018

Aprinoia Therapeutics is a Taipei, Taiwan–based clinical-stage neuroscience biopharmaceutical company led by founder and CEO Ming-Kuei Jang. The company is advancing three diagnostic and two therapeutic product candidates targeting Alzheimer’s disease, non‑AD tauopathies, Lewy body dementia and Parkinson’s disease. Its most advanced asset is the tau PET imaging tracer 18F‑PM‑PBB3, which showed potential to visualize tau pathologies in Alzheimer’s and progressive supranuclear palsy patients in early 2017 clinical studies. Aprinoia has operations in Taiwan, China and Japan and operates across preclinical and clinical stages. The company focuses on both imaging diagnostics and therapeutic pipelines and plans to use new capital to advance those programs through preclinical and clinical development.

Participated · Series B · Jun 2014

JHL Biotech focuses on developing and manufacturing affordable biologic medicines, with an emphasis on biosimilars, bioengineering and innovative manufacturing solutions. The company provides process development and cGMP manufacturing services and helps global partners access the China market. JHL's pipeline includes proprietary biosimilar compounds and a pre-clinical novel therapeutic portfolio. The company plans to use new funding to continue biosimilar programs through clinical trials, construct a fill-finish facility at its Wuhan commercial manufacturing plant, expand its pre-clinical novel therapeutic portfolio, and support working capital. With the Series C proceeds, JHL has secured capital necessary to complete full development and BLA filing of at least two of its proprietary biosimilar compounds. Founded in 2012 and led by President and CEO Racho Jordanov, the company is based in Hsinchu. Founded in December 2012 and led by President and CEO Racho Jordanov, JHL Biotech focuses on bioengineering and product development under current Good Manufacturing Practices (cGMP). The company has five biosimilar programs and one new molecular entity in development, with an emphasis on biosimilar monoclonal antibodies. It completed construction of a clinical manufacturing facility in Hsinchu, Taiwan in December 2013 and has formed partnerships with domestic academic and government institutions as well as regional and global biotech and pharmaceutical companies. JHL plans to submit its first clinical trial and investigational new drug (IND) applications in 2015. Financially, it closed a $35M Series B to fund development of its biosimilar mAb pipeline, accelerate IND filings, support facility expansion in Taiwan, and acquire equipment for a commercial manufacturing facility in Wuhan, China expected to be completed by 2014 year-end. The financing is intended to support both R&D progress and commercial manufacturing build-out.